Situation of the Prescription service

Abilita Hälsovård / Abilita Oy Ab

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information			20102016 / 30.12.2016

Acute / Acuvitec Oy

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information			20012016 / 30.11.2016

AssisDent / Entteri Professional Software Oy

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information			20062016 / 27.12.2016

DomaCare Medi / Invian Oy

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
Refusal to share prescription information		1. Ongoing,  20.2.2018 2. Not tested 3. Not tested
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9			20142017 / 14.3.2017

1 = Testing between system supplier and Kela, 2 = Testing between client test organisation and Kela, 3 = Cross-testing.

DynamicHealth / Tieto Healthcare & Welfare Oy

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information			20032016 / 30.12.2016

Effica / Tieto Healthcare & Welfare Oy

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information			20032016 / 9.12.2016

Epic / Epic Helsinki Oy

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.42 and requirement specifications 2.9, Refusal to share prescription information			20022018 / 5.10.2018

eRA / Atostek Oy

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information			20092016 / 29.12.2016

ESKO / PPSHP

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information			20022016 / 9.12.2016

GFS / CGI Oy

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information			25.11.2016

Hilkka / FastROI Oy

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9			20082016 / 30.12.2016
Refusal to share prescription information			20012018 / 11.1.2018

Kelain / Kela

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
Functionality for action on behalf of a minor	4.12.2019	1. Completed, 10.12.2019 2. Not tested 3. Not tested
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9			20042016 / 9.12.2016
Refusal to share prescription information			20202017 / 1.6.2017

1 = Testing between system supplier and Kela, 2 = Testing between client test organisation and Kela, 3 = Cross-testing.

Lifecare /Tieto Healthcare & Welfare Oy

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information			20192017 / 11.5.2017

MAXX /Receptum Oy 

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information			20122017 / 11.1.2017
Cross-border prescription			20012019 / 30.9.2019

Mediatri / Mediconsult Oy

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9			20072016 / 30.12.2016
Refusal to share prescription information			20212017 / 5.6.2017

Mediresepti / Mediconsult Oy

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9			20132016 / 30.12.2016
Refusal to share prescription information			20222017 / 4.12.2017

Navitas / Elisa Appelsiini Oy

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Refusal to share prescription information			20182017 / 24.2.2017

pd3 / Pharmadata Oy

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information			20172017 / 27.1.2017

Pegasos / CGI Oy

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information			20052016 / 20.12.2016

Salix / Pharmadata Oy

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information			20162017 / 27.1.2017
Cross-border prescription			20022019 / 10.12.2019

SoftMedic / CGI Oy

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information			22.11.2016

Uranus / CGI Oy

	Registration, return date of pre-test cases	Testing phases start date	Statement number and date
Ongoing joint testings:
No ongoing joint testings
Accepted joint testings:
Prescription's MR and CDA R2 specifications 3.41/3.42 and requirement specifications 2.8/2.9, Refusal to share prescription information			20152017 / 11.1.2017